Jinsong Li

Dr. Jinsong Li

Central south university

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2020 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
SCShijie Chen
Shijie Chen
YLYuezhan Li
Yuezhan Li
SZShuang Zhi
Shuang Zhi
ZDZhiyu Ding
Zhiyu Ding
WWWeiguo Wang
Weiguo Wang
JLJinsong Li
Jinsong Li
N6-methyladenosine (m6A) regulators are involved in the progression of various cancers via regulating m6A modification. However, the potential role and mechanism of the m6A modification in osteosarcoma remains obscure. In this study, WTAP was found to be highly expressed in osteosarcoma tissue and it was an independent prognostic factor for overall survival in osteosarcoma. Functionally, WTAP, as an oncogene, was involved in the proliferation and metastasis of osteosarcoma in vitro and vivo. Mechanistically, M6A dot blot, RNA-seq and MeRIP-seq, MeRIP-qRT-PCR and luciferase reporter assays showed that HMBOX1 was identified as the target gene of WTAP, which regulated HMBOX1 stability depending on m6A modification at the 3′UTR of HMBOX1 mRNA. In addition, HMBOX1 expression was downregulated in osteosarcoma and was an independent prognostic factor for overall survival in osteosarcoma patients. Silenced HMBOX1 evidently attenuated shWTAP-mediated suppression on osteosarcoma growth and metastasis in vivo and vitro. Finally, WTAP/HMBOX1 regulated osteosarcoma growth and metastasis via PI3K/AKT pathway. In conclusion, this study demonstrated the critical role of the WTAP-mediated m6A modification in the progression of osteosarcoma, which could provide novel insights into osteosarcoma treatment.

1 January 2020 in Aging and disease
Verified
Journal Article
Open access
PDF file
SCShijie Chen
Shijie Chen
YLYuezhan Li
Yuezhan Li
SZShuang Zhi
Shuang Zhi
ZDZhiyu Ding
Zhiyu Ding
YHYan Huang
Yan Huang
JLJinsong Li
Jinsong Li
The switch between osteogenic and adipogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) plays a key role in aging-induced osteoporosis. In this study, miR-19a-3p was obviously downregulated in BMSCs from aged humans and mice. Overexpressed miR-19a-3p evidently reduced aging-induced bone loss in mice and promoted osteogenic differentiation of BMSCs, while silenced miR-19a-3p manifestly increased aging-induced bone loss in mice and repressed osteogenic differentiation of BMSCs. Hoxa5 was significantly downregulated in the BMSCs from aged mice and contribute to miR-19a-3p-induced osteoblast differentiation as a direct target gene of miR-19a-3p. Furthermore, lncRNA Xist was found as a sponge of miR-19a-3p to repress BMSCs osteogenic differentiation. In conclusion, our study reveals the critical role of the lncRNA Xist/miR-19a-3p/Hoxa5 pathway in aging-induced osteogenic differentiation of BMSCs, indicating the potential therapeutic target for osteoporosis.

16 July 2025 in Materials Today Bio
Verified
Journal Article
Open access
JLJinsong Li
Jinsong Li
ZDZhiyu Ding
Zhiyu Ding
JLJieling Liu
Jieling Liu
GLGuanqi Li
Guanqi Li
YLYuezhan Li
Yuezhan Li
LCLingyan Cao
Lingyan Cao
T-cell-based immunotherapy shows significant promise for treating osteosarcoma. However, its effectiveness is often limited by the immunosuppressive tumor environment and weakened T-cell activity. In this study, we present a tumor-targeting strategy that aims to reshape the tumor microenvironment and modulate T-cell function using a hierarchical metal-organic framework (MOF). The MOF is armed with PD-L1 antibody (anti-PD-L1) and loaded with C-C motif chemokine ligand 19 (CCL19) and oxaliplatin in separate layers, which enhances the therapeutic efficiency for osteosarcoma. The intricate hierarchical MOFs employed in this research provide a programmable action schedule for the loaded drugs, enabling spatiotemporal control over their release and action. The anti-PD-L1 on the surface of nanoparticles specifically binds to PD-L1 on tumor cells, reinforcing the targeting and recognition capabilities of the materials. Additionally, this targeted approach serves as an immune checkpoint inhibitors therapy, blocking the binding of PD-1 and PD-L1 between T cells and tumor cells. This prevents T-cell exhaustion, thereby restoring their killing ability. Moreover, the initial release of CCL19 from the nanoparticles recruits more T cells into the tumor microenvironment, augmenting the immunotherapy effect. As a result, when oxaliplatin is pH-responsively released from the nanoparticles upon being absorbed by osteosarcoma cells, it exhibits maximum killing ability against the cancer cells. In vivo studies demonstrated that the developed nanosystem exhibited an anti-tumor effect, resulting in a tumor suppression rate exceeding 90 % while causing minimal side effects. This comprehensive approach inhibits tumor growth and metastasis with minimal side effects, demonstrating the positive efficacy of combining immunotherapy and conventional chemotherapy in osteosarcoma treatment. Furthermore, the developed nanoparticles not only have a high drug loading capacity but also prevent mutual interference between different drugs, allowing each drug to exert its optimal effect. This study introduces a promising paradigm for the field of immunochemotherapy and offers potential advancements in the treatment of osteosarcoma.

16 April 2024 in Journal of Orthopaedic Surgery and Research
Verified
Journal Article
Open access
PDF file
HGHubing Guo
Hubing Guo
LYLingxia Yang
Lingxia Yang
JLJin Liu
Jin Liu
LCLiqi Chen
Liqi Chen
YHYufeng Huang
Yufeng Huang
JLJinsong Li
Jinsong Li
Background: Ossification of ligamentum flavum (OLF) is a prevalent degenerative spinal disease, typically causing severe neurological dysfunction. Kruppel-like factor 5 (KLF5) plays an essential role in the regulation of skeletal development. However, the mechanism KLF5 plays in OLF remains unclear, necessitating further investigative studies. Methods: qRT-PCR, immunofluorescent staining and western blot were used to measure the expression of KLF5. Alkaline Phosphatase (ALP) staining, Alizarin red staining (ARS), and the expression of Runt-related transcription factor 2 (RUNX2), osteopontin (OPN), and osteocalcin (OCN) were used to evaluate the osteogenic differentiation. Luciferase activity assay and ChIP-PCR were performed to investigate the molecular mechanisms. Results: KLF5 was significantly upregulated in OLF fibroblasts in contrast to normal ligamentum flavum (LF) fibroblasts. Silencing KLF5 diminished osteogenic markers and mineralized nodules, while its overexpression had the opposite effect, confirming KLF5’s role in promoting ossification. Moreover, KLF5 promotes the ossification of LF by activating the transcription of Connexin 43 (CX43), and overexpressing CX43 could reverse the suppressive impact of KLF5 knockdown on OLF fibroblasts’ osteogenesis. Conclusion: KLF5 promotes the OLF by transcriptionally activating CX43. This finding contributes significantly to our understanding of OLF and may provide new therapeutic targets.

1 September 2024 in Breast Cancer: Targets and Therapy
Verified
Journal Article
Open access
PDF file
RLRuixi Li
Ruixi Li
LLLulu Liu
Lulu Liu
YLYong Liu
Yong Liu
JTJiang Tang
Jiang Tang
JLJinsong Li
Jinsong Li
Introduction: Protocadherin 9 (PCDH9), a member of the cadherin superfamily of transmembrane proteins, plays a role in cell adhesion and neural development. Recent studies suggest that PCDH9 may function as a tumor suppressor in certain cancers, though its specific role in breast cancer remains unclear. Methods: UALCAN database to retrieve information on PCDH9 expression in breast cancer tissues compared with that in normal tissues. The biological effects of PCDH9 in breast cancer cells were analyzed using the DepMap database. Stable knockdown or overexpression of PCDH9 in breast cancer cell lines and subsequently assessed tumor cell proliferation and migration. Synthetic lethal screening was conducted for breast cancer cells with low PCDH9 expression or deficiency. Results: In this study, we observed significant downregulation of PCDH9 in breast cancer tissues, with its expression negatively correlated with progression-free survival. Further investigations revealed that decreased PCDH9 expression promotes breast cancer cell proliferation and migration, while overexpression of PCDH9 has the opposite effect. Subsequently, we identified the TAS-102, an approved drug for metastatic colorectal cancer, exhibited selective cytotoxicity against breast cancer cells with low PCDH9 expression. Conclusion and discussion: In summary, our study identified PCDH9 as a tumor suppressor in breast cancer and highlighted TAS-102 as a potential therapeutic option for tumors with low PCDH9 expression or deficiency. The specific interaction between TAS-102 and PCDH9 warrants further exploration, providing deeper insights into its mode of action in treating PCDH9-deficient breast cancer.

16 December 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JGJianfang Gao
Jianfang Gao
JQJina Qing
Jina Qing
XLXianglong Li
Xianglong Li
YLYuxuan Luo
Yuxuan Luo
LHLingwen Huang
Lingwen Huang
SHShanping He
Shanping He
Mechanistic target of rapamycin complex 1 (mTORC1) is a master controller of cell growth, and its dysregulation is associated with cancer. KICSTOR, a complex comprising KPTN, ITFG2, C12orf66, and SZT2, functions as a critical negative regulator of amino acid–induced mTORC1 activation. However, the regulatory mechanisms governing KICSTOR remain largely unclear. In this study, we identify F-box only protein 2 (FBXO2) as a key modulator of amino acid–dependent mTORC1 signaling. Mechanistically, FBXO2 colocalizes and directly interacts with KPTN via its F-box–associated domain, promoting K48- and K63-linked polyubiquitination of KPTN at lysine residues 49, 67, 262, and 265. FBXO2-mediated KPTN ubiquitination disrupted its interaction with ITFG2 and SZT2, while enhancing its interaction with C12orf66, thereby impairing the ability of KICSTOR to recruit the GATOR1 complex — comprising DEPDC5, NPRL2, and NPRL3 — to the lysosomal surface. Notably, FBXO2 protein levels were substantially upregulated in patients with liver cancer, and FBXO2-mediated KPTN ubiquitination facilitated the progression of hepatocellular carcinoma (HCC). These results reveal a key regulatory mechanism of mTORC1 signaling and highlight FBXO2 and KPTN ubiquitination as therapeutic targets for HCC treatment.